And that’s exactly where things get personal.
Understanding PSA: What the Number Actually Means
Prostate-specific antigen. Sounds technical, sterile — like something pulled from a lab manual. But PSA is just a protein made by the prostate, whether healthy, enlarged, or cancerous. The test measures how much of it leaks into your bloodstream. Simple in theory. A blood draw, a machine reading, a number. Done.
Yet that number means different things depending on who you are, how old you are, and what your doctor chooses to do with it. It is not — let’s be clear about this — a cancer test. It's a screen. A hint. A whisper in a noisy room. A man can have aggressive prostate cancer and a PSA of 2.8. Another can have a level of 6.5 and nothing but benign enlargement — which, by the way, affects more than 70% of men over 60.
And because the prostate naturally grows with age, PSA levels tend to creep upward too. That’s why comparing a 70-year-old’s result to a 50-year-old’s is like comparing apples to lawnmowers. It doesn’t work.
I am convinced that one-size-fits-all thresholds — like the old “4.0 ng/mL” rule — do more harm than good. They create anxiety. Unnecessary biopsies. Overtreatment. And yet, abandoning PSA testing altogether? That changes everything — and not for the better.
How PSA Levels Change with Age
By the time a man hits 70, his prostate has likely been growing for decades. Think about it: from age 40 onward, it expands at about 1.6% per year on average. That gradual swelling pushes PSA up — not because of cancer, but because more prostate tissue equals more PSA production.
Studies from the Prostate Cancer Research International: Active Surveillance (PRIAS) project show that the median PSA for men in their early 70s is around 1.7 ng/mL — but the upper limit of what’s considered “normal” can reach 6.5 ng/mL, depending on baseline health and prostate volume. A 1996 study in the New England Journal of Medicine of over 900 men without prostate cancer found average levels rising from 0.7 ng/mL in men aged 40–49 to 2.8 ng/mL by age 70–79.
That’s not alarming. It’s expected. But if you walk into a clinic with a 3.2 and no context? You might get a biopsy. You might not need one.
Why Lab Variability Matters More Than You Think
Not all PSA tests are created equal. Two labs can run the same blood sample and return results differing by 0.8 ng/mL. That’s not a typo. It happens. Factors like reagent brands, calibration methods, and even technician experience play a role. So if your PSA jumps from 3.1 to 3.9 between two clinics — and they used different labs — it might not be your prostate changing. It might be the machine.
Which explains why urologists increasingly emphasize tracking trends over time, not isolated numbers. One reading means very little. Five readings over five years? That tells a story.
When Should You Worry? Interpreting Results Beyond the Number
A PSA of 4.5 at age 70 isn’t automatically dangerous — but it demands attention. The real signal isn’t the number itself. It’s how fast it’s rising. A sudden spike from 2.1 to 5.3 in 12 months? That’s a red flag. A slow climb from 3.0 to 3.8 over five years? Less concerning.
Doctors look at velocity. Doubling time. Free-to-total PSA ratios. Digital rectal exams. Family history. Even ethnicity — Black men face higher prostate cancer risk and often present with higher PSA levels. All of this shapes interpretation.
Take Mr. Jenkins from Des Moines, 72. PSA: 5.1. No symptoms. No family history. Prostate feels normal on exam. His doctor waits. Watches. Repeats the test in six months. It’s 5.3. Still no rush. Now, Mr. Rivera, 71. Same PSA. But his father died of prostate cancer. His brother had radiation at 68. His PSA rose from 3.7 to 5.1 in 18 months. Different conversation. Entirely.
Because medicine isn’t math. It’s context.
PSA Velocity: The Speed That Matters More Than the Number
If your PSA increases by more than 0.75 ng/mL per year — especially above age 60 — that changes everything. That rate suggests something biologically active might be happening, whether inflammation, infection, or malignancy. One 2006 study published in the Journal of the National Cancer Institute found men with a velocity over 0.35 ng/mL/year had a significantly higher risk of aggressive cancer, independent of absolute PSA level.
Which is why smart monitoring means consistent testing — same lab, same protocol — every 12 to 18 months for men in this age group considering screening.
Free vs. Total PSA: A Deeper Look
Total PSA measures all the antigen in your blood. Free PSA measures the portion not bound to proteins. The lower the free PSA percentage, the higher the chance of cancer. For men with total PSA between 4.0 and 10.0 ng/mL, a free PSA under 10% indicates a 56% probability of cancer; above 25%, it drops to 8%. This test isn’t perfect — but it can prevent unnecessary biopsies. And that’s worth something.
Beyond the Screening: Risks of Overdiagnosis and Overtreatment
Here’s the uncomfortable truth: not all prostate cancers need treatment. Some grow so slowly they’ll never cause symptoms — let alone death. And yet, because we detect them via PSA, many men undergo surgery or radiation with real side effects: incontinence, erectile dysfunction, bowel issues. Studies suggest up to 50% of men treated for low-risk prostate cancer may have been better off monitored.
The U.S. Preventive Services Task Force (USPSTF) revised its stance in 2018, recommending shared decision-making between men aged 55–69 and their doctors — with no blanket endorsement for routine screening. For men 70 and older? The guidance is even sharper: screening should not be routine. The risks often outweigh the benefits.
Because a 10-year life expectancy matters. If you’re 70 with multiple health issues — heart disease, diabetes, COPD — and a life expectancy under 10–15 years, treating a low-grade cancer may offer no survival benefit. In short: you’re more likely to die with it than from it.
We’re far from it in accepting that not all cancers must be attacked. But we’re getting closer.
PSA Testing: Alternatives and Modern Approaches
Is PSA obsolete? No. But it’s evolving. New tools are reshaping the conversation.
MRI Before Biopsy: A Game Changer
In the past, a rising PSA led straight to biopsy — 12 blind needle sticks into the prostate. Painful. Risky. Often unnecessary. Now, multiparametric MRI is changing that. It can identify suspicious areas — or rule them out — before any needles enter the body. In the UK, the PRECISION trial showed MRI-guided biopsy detected more clinically significant cancers and fewer insignificant ones than standard methods. As a result: fewer biopsies, better targeting, less overtreatment.
Cost? Between $1,200 and $2,500 in the U.S., not always covered by insurance. But for men on the fence, it’s a powerful intermediate step.
Biomarker Tests: Beyond the Standard PSA
Tests like the 4Kscore, PHI (Prostate Health Index), and PCA3 analyze multiple markers in blood or urine to better predict cancer risk. The 4Kscore, for example, combines four kallikreins with clinical data to estimate the likelihood of high-grade cancer. A man with a PSA of 4.2 but a 4Kscore of 5%? Probably safe to monitor. One with a 35% score? Needs closer look.
These aren’t replacements. They’re refinements. And they’re slowly gaining ground in clinical practice — especially in men with borderline results.
Frequently Asked Questions
Should All 70-Year-Old Men Get PSA Tests?
No. The American Cancer Society says men 70+ with no symptoms and average risk should not be routinely screened. Shared decision-making matters. Talk to your doctor. Consider your health. Your values. Your life expectancy. Because screening isn’t free — not in anxiety, cost, or complications.
Can Medications Affect PSA Levels?
Yes. Finasteride (Proscar) and dutasteride (Avodart), used for enlarged prostates, can lower PSA by 50% or more. If you’re on one, your doctor should double the result before interpreting it. Aspirin, statins, even coffee — some studies suggest slight suppression. Never read the tea leaves alone.
What Happens If My PSA Is High?
Don’t panic. Repeat the test. Rule out infection. Consider MRI. Assess velocity. Look at free PSA. And — this is key — don’t jump to biopsy. Ask: “What are we trying to find? And what will we do if we find it?” Because knowledge without actionability creates stress, not clarity.
The Bottom Line
A “normal” PSA for a 70-year-old isn’t a single number. It’s a range — loosely between 1.0 and 6.5 ng/mL — shaped by age, prostate size, and personal risk. But even that’s too simplistic. The thing is, we’ve spent decades chasing thresholds when we should’ve been chasing meaning. A PSA of 3.8 might be fine for one man. For another, it’s the first whisper of trouble.
I find this overrated: the idea that early detection always wins. Sometimes, it just starts a cascade of interventions that do more harm than good. My personal recommendation? If you’re 70, healthy, and want screening — fine. But commit to monitoring trends, not snapshots. Insist on MRI before biopsy if possible. And never, ever let a single number dictate your next move without context.
Because prostate health at this age isn’t about fear. It’s about judgment. And honestly, it is unclear how many lives PSA screening actually saves in men over 70 — but we do know it generates a lot of anxiety. So tread carefully. Ask questions. And remember: you’re not just a number on a lab report. You’re a person with a life, a history, and a right to decide what’s worth knowing — and what’s not.